Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    The U.S. Food and Drug Administration approved a new indication for Xywav for idiopathic hypersomnia in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of cataplexy or excessive daytime sleepiness in patients seven years or older with narcolepsy.

  • SCHOTT and Serum Institute of India Announce Joint Venture for Pharmaceutical Packaging

    Germanys specialty glass company SCHOTT AG has a new partner: Serum Institute of India, the world's largest vaccine producer and manufacturer of highly-effective biologies, has bought the 50% stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry. The joint venture is the leading Indian manufacturer of pharma packaging products such as vials, syringes, ampoules and cartridges used to package life-saving medications.

  • Microbes turn back the clock as UCC research discovers their potential to reverse aging in the brain

    Research from APC Microbiome Ireland (APC) SFI Research Centre at University College Cork (UCC) published today in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function via the microbes in the gut.

  • Growing evidence of vitamin K benefits for heart health

    New Edith Cowan University (ECU) research has found that people who eat a diet rich in vitamin K have up to a 34 percent lower risk of atherosclerosis-related cardiovascular disease (conditions affecting the heart or blood vessels).

  • Novavax submits Recombinant COVID-19 Vaccine for approval in India

    Novavax, Inc a biotechnology company developing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submissions were made to the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.

  • J&J COVID-19 vaccine gets approval, says Health Minister of India

     Mansukh Mandaviya, Minister of Health and Family Welfare; Chemicals and Fertilizers, Government of India has announced that Johnson and Johnson single-dose COVID-19 vaccine is given approval for Emergency Use in India.

    He said that India expands its vaccine basket. Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines.

  • New study details enzyme that allows coronavirus to resist antiviral medications

    The coronavirus that causes COVID-19 has demonstrated a stubborn ability to resist most nucleoside antiviral treatments, but a new study led by an Iowa State University scientist could help to overcome the virus’s defenses.

  • An overactive sweet tooth may spell trouble for our cellular powerplants

    The average American eats roughly 22 teaspoons of added sugar a day — more than three times the recommended amount for women and more than double the recommended amount for men. Although this overconsumption is known to contribute to Type 2 diabetes and other disorders, the exact ways in which eating too much sugar sets the stage for metabolic diseases on a cellular level has been less clear.

  • Scientists discover a new way to detect early colon cancer

    Colon cancer is one of the most common types of cancer – both in India and worldwide. According to the Indian Council of Medical Research (ICMR), it is the third most common cancer in men (6, 63,000 cases in 2014, 10.0% of all cancer cases) and the second most common in women (5, 71,000 cases in 2014, 9.4% of all cancer cases).

  • US FDA grants Priority Review to Roches Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

    Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test.

Subscribe to Pharma News